These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 31856742)

  • 21. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
    BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
    Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
    Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
    Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
    Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study.
    Trentesaux V; Maiezza S; Bogart E; Le Deley MC; Meyer E; Vanquin L; Pasquier D; Mortier L; Mirabel X
    Front Oncol; 2024; 14():1322515. PubMed ID: 38505592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?
    Franzese C; Badalamenti M; Comito T; Franceschini D; Clerici E; Navarria P; Loi M; D'agostino G; Baldaccini D; Chiola I; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Radiother Oncol; 2020 Sep; 150():184-190. PubMed ID: 32593644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?
    Aquilano M; Loi M; Visani L; Livi L; Nuyttens JJ
    Acta Oncol; 2023 Mar; 62(3):298-304. PubMed ID: 36905644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
    Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
    J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy.
    Klement RJ; Hoerner-Rieber J; Adebahr S; Andratschke N; Blanck O; Boda-Heggemann J; Duma M; Eble MJ; Eich HC; Flentje M; Gerum S; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl KH; Klass ND; Krempien R; Lohaus F; Petersen C; Schrade E; Wendt TG; Wittig A; Guckenberger M
    Radiother Oncol; 2018 May; 127(2):246-252. PubMed ID: 29510865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression.
    Pembroke CA; Fortin B; Kopek N
    Radiother Oncol; 2018 Jun; 127(3):493-500. PubMed ID: 29735409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
    Triggiani L; Alongi F; Buglione M; Detti B; Santoni R; Bruni A; Maranzano E; Lohr F; D'Angelillo R; Magli A; Bonetta A; Mazzola R; Pasinetti N; Francolini G; Ingrosso G; Trippa F; Fersino S; Borghetti P; Ghirardelli P; Magrini SM
    Br J Cancer; 2017 Jun; 116(12):1520-1525. PubMed ID: 28449007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
    Onal C; Gultekin M; Oymak E; Guler OC; Yilmaz MT; Yuce Sari S; Akkus Yildirim B; Yildiz F
    Int J Gynecol Cancer; 2020 Jun; 30(6):865-872. PubMed ID: 32273293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
    Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
    Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of oligometastatic or oligoprogression cancer].
    Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
    Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
    Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy.
    Franzese C; Comito T; Toska E; Tozzi A; Clerici E; De Rose F; Franceschini D; Navarria P; Reggiori G; Tomatis S; Scorsetti M
    Radiother Oncol; 2019 Apr; 133():220-226. PubMed ID: 30414754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies.
    Franzese C; Francolini G; Nicosia L; Alongi F; Livi L; Scorsetti M
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):50-56. PubMed ID: 32723486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
    Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic body radiotherapy for lung oligometastases: Literature review according to PICO criteria.
    Alongi F; Mazzola R; Figlia V; Guckenberger M
    Tumori; 2018 Jun; 104(3):148-156. PubMed ID: 29714665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.